Scholar Rock Holding Revenue 2017-2022 | SRRK

Scholar Rock Holding revenue from 2017 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Scholar Rock Holding Annual Revenue
(Millions of US $)
2021 $19
2020 $15
2019 $20
2018 $
2017 $
2016 $0
Scholar Rock Holding Quarterly Revenue
(Millions of US $)
2022-09-30
2022-06-30
2022-03-31 $33
2021-12-31 $4
2021-09-30 $5
2021-06-30 $5
2021-03-31 $5
2020-12-31 $3
2020-09-30 $3
2020-06-30 $4
2020-03-31 $5
2019-12-31 $8
2019-09-30 $5
2019-06-30 $5
2019-03-31 $3
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.637B $0.019B
Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
Emergent Biosolutions (EBS) United States $0.671B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.359B 0.00
Ambrx Biopharma (AMAM) United States $0.083B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00